TNNI3 and myocardial infarction: Despite identifying more patients at risk, the rate of subsequent type 1 or 4b myocardial infarction or cardiovascular death at 1 year in all patients with an elevated hs-cTnI concentration was similar before and after use in those with (25% vs 24%; adjusted hazard ratio [aHR], 1.00; 95% CI, 0.85-1.18) and without kidney impairment (13% vs 11%; aHR, 0.89; 95% CI, 0.73-1.08) (Table).